Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Verzenio

- PMLiVE

Lynparza set for further expansion with EU approval in breast cancer

Companies have prostate cancer and pancreatic cancer in their sights

- PMLiVE

NICE nod for Lilly’s breast cancer drug Verzenio via CDF

Helps Lilly drug in pursuit of Ibrance and Kisqali

AstraZeneca AZ

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

Filing due later this year

- PMLiVE

Lilly and ImmuNext deal focused on autoimmune diseases

Aiming for targets upstream of existing checkpoint regulators

Brain power: fresh approaches to Alzheimer’s drug discovery

New alliances are learning from past mistakes and breaking down research barriers

- PMLiVE

Trulicity’s ascent lifts Lilly

Diabetes treatment leads new product growth

- PMLiVE

EMA says Lilly’s Lartruvo should not be prescribed

First time EMA has acted on accelerated approval follow-up

- PMLiVE

NICE gives Lilly’s Verzenios chance to compete with rivals

Breast cancer drug also being appraised in novel combination

Eli Lilly HQ

Lilly adds to pharma M&A run with $8bn Loxo buy-out

Lilly claims company ahead of more dominant oncology players

- PMLiVE

Lilly partners with AC Immune on tau drug for Alzheimer’s

Potential payments of $1.7bn to Swiss firm

- PMLiVE

Roche gains speedy review for Tecentriq in first-line breast cancer

Set to become the first immunotherapy for triple negative breast cancer

Eli Lilly HQ

Lilly gets EMA nod for Verzenio in breast cancer

And puts pressure on Pfizer’s market leading Ibrance and Novartis’ Kisqali

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links